Literature DB >> 25332646

A reliable frozen section technique for basal cell carcinomas of the head and neck.

Wisam Menesi1, Edward W Buchel2, Thomas Je Hayakawa2.   

Abstract

Basal cell carcinomas (BCCs) of the head and neck treated by conventional techniques of surgical excision, curettage, cryotherapy and radiation therapy have recurrence rates of up to 42%. Mohs micrographic surgery (MMS) decreases the recurrence rate but can be expensive, delay definitive reconstruction and is limited in its availability. The authors report a series of 50 patients with head and neck BCCs treated by a surgeon-directed 'en face' frozen section technique that immediately evaluates the entire peripheral and deep margins during BCC resection, and potentially offers a more efficient and equally effective alternative to MMS. Patient demographics, pathology results, operative time, technique and outcomes are all reported. With a mean follow-up of three years, there was only one recurrence (1.7%). Mean total operative time was 1 h 47 min. The authors conclude that this surgeon-directed 'en face' frozen section technique does not require any specialized training, enables more rapid and reliable results than standard frozen section techniques that are currently used, and provides outcomes equivalent to MMS in the surgical treatment of head and neck BCCs.

Entities:  

Keywords:  Basal cell carcinoma; Carcinoma; En face; Frozen section; Mohs surgery; Treatment

Year:  2014        PMID: 25332646      PMCID: PMC4173865     

Source DB:  PubMed          Journal:  Plast Surg (Oakv)        ISSN: 2292-5503            Impact factor:   0.947


  28 in total

1.  How accurate is frozen section for skin cancers?

Authors:  Mark Eric Manstein; Carl H Manstein; Roberta Smith
Journal:  Ann Plast Surg       Date:  2003-06       Impact factor: 1.539

2.  Metastasizing basal cell carcinomas.

Authors:  R S COTRAN
Journal:  Cancer       Date:  1961 Sep-Oct       Impact factor: 6.860

3.  Recurrence rates of treated basal cell carcinomas. Part 4: X-ray therapy.

Authors:  M K Silverman; A W Kopf; A H Gladstein; R S Bart; C M Grin; M J Levenstein
Journal:  J Dermatol Surg Oncol       Date:  1992-07

4.  How accurate is the visual assessment of basal carcinoma margins?

Authors:  E Epstein
Journal:  Br J Dermatol       Date:  1973-07       Impact factor: 9.302

Review 5.  Mohs micrographic surgery for facial skin cancer.

Authors:  H D Vuyk; P J Lohuis
Journal:  Clin Otolaryngol Allied Sci       Date:  2001-08

6.  Five-year results of Mohs' micrographic surgery for aggressive facial basal cell carcinoma in Sweden.

Authors:  A M Wennberg; O Larkö; B Stenquist
Journal:  Acta Derm Venereol       Date:  1999-09       Impact factor: 4.437

7.  Cost-effectiveness of Mohs Micrographic Surgery vs Surgical Excision for Basal Cell Carcinoma of the Face.

Authors:  Brigitte A B Essers; Carmen D Dirksen; Fred H M Nieman; Nicole W J Smeets; Gertrude A M Krekels; Martin H Prins; H A Martino Neumann
Journal:  Arch Dermatol       Date:  2006-02

8.  Recurrent basal cell carcinoma. A review concerning the incidence, behavior, and management of recurrent basal cell carcinoma, with emphasis on the incompletely excised lesion.

Authors:  L Koplin; H A Zarem
Journal:  Plast Reconstr Surg       Date:  1980-05       Impact factor: 4.730

9.  Basal cell carcinoma with pulmonary and lymph node metastasis causing death.

Authors:  June K Robinson; Madhu Dahiya
Journal:  Arch Dermatol       Date:  2003-05

10.  Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma.

Authors:  D E Rowe; R J Carroll; C L Day
Journal:  J Dermatol Surg Oncol       Date:  1989-04
View more
  2 in total

1.  The practice patterns in the management of sebaceous carcinoma of the eyelid in the Asia Pacific region.

Authors:  Janice J C Cheung; Bita Esmaeli; Stacey C Lam; Tracey Kwok; Hunter K L Yuen
Journal:  Eye (Lond)       Date:  2019-04-05       Impact factor: 3.775

2.  Intraoperative assessment of surgical margins using "en face" frozen sections in the management of cutaneous carcinomas.

Authors:  Ana Carolina Vasconcellos Guedes Otsuka; Eduardo Bertolli; Mariana Petaccia de Macedo; Clovis Antonio Lopes Pinto; João Pedreira Duprat Neto
Journal:  An Bras Dermatol       Date:  2022-07-05       Impact factor: 2.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.